

Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus

Dzyurkevich M., Babkov D., Shtyrlin N., Mayka O., Iksanova A., Vassiliev P., Balakin K., Spasov A., Tarasov V., Barreto G., Shtyrlin Y., Aliev G.

Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

Abstract

© 2017 The Author(s). Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered as one of the most promising strategies for the treatment of type 2 diabetes mellitus. In this work, a series of novel symmetric molecular constructs, in which two pyridoxine moieties are connected via sulfur-containing linkers, have been synthesized and tested in vitro for glucokinase activation potential. The enzyme activation rates by two most active compounds at 100 μ M (~150% and 130%) were comparable to that of the reference agent PF-04937319 (~154%). Both leading compounds demonstrated low cytotoxicity and excellent safety profile in acute toxicity experiment in rats after oral administration with LD 50 exceeding 2000 mg/kg of body weight. Binding mode of the active compounds in comparison with the reference agent was studied using molecular docking. The leading compounds represent viable preclinical candidates for the treatment of type 2 diabetes mellitus, as well as a promising starting point for the design of structural analogs with improved activity.

<http://dx.doi.org/10.1038/s41598-017-16405-2>

References

- [1] Global Report on Diabetes. (2016).
- [2] Kanthlal, S. K. et al. An updated compact review on diabetes and molecular target of oral hypoglycemic agents. *Res. J. Pharmacol.* 8, 6-12 (2014).
- [3] González-Reyes, R. E., Aliev, G., Ávila-Rodrigues, M. & Barreto, G. E. Alterations in glucose metabolism on cognition: A possible link between diabetes and dementia. *Curr. Pharm. Des.* 22, 812-818 (2016).
- [4] Maksimov, M. L. et al. Approaches for the development of drugs for treatment of obesity and metabolic syndrome. *Curr. Pharm. Des.* 22, 895-903 (2016).
- [5] Jurado-Coronel, J. C. et al. Implication of green tea as a possible therapeutic approach for Parkinson disease. *CNS Neurol. Disord.-Drug Targets* 15, 292-300 (2016).
- [6] Agius, L. Glucokinase and molecular aspects of liver glycogen metabolism. *Biochem. J.* 414, 1-18 (2008).
- [7] Grimsby, J. et al. Allosteric activators of glucokinase: Potential role in diabetes therapy. *Science* (80-.). 301, 370-373 (2003).
- [8] Zhi, J. & Zhai, S. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus. *J. Clin. Pharmacol.* 56, 231-238 (2016).
- [9] Katz, L. et al. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. *Diabetes, Obes. Metab.* 18, 191-195 (2016).

- [10] Amin, N. B. et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. *Diabetes, Obes. Metab.* 17, 751-759 (2015).
- [11] Xu, H. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: Results from a first-in-human single ascending dose study. *Drug Des. Devel. Ther.* 10, 1619-1626 (2016).
- [12] Filipski, K., Futatsugi, K., Pfefferkorn, J. & Stevens, B. Glucokinase activators. *Pharm. Pat. Anal.* 1, 301-311 (2012).
- [13] Pugachev, M. V. et al. Synthesis and antibacterial activity of novel phosphonium salts on the basis of pyridoxine. *Bioorganic Med. Chem.* 21, 4388-4395 (2013).
- [14] Shtyrilin, N. V. et al. Theoretical and experimental study on cyclic 6-methyl-2, 3, 4-tris(hydroxymethyl)pyridin-5-ol acetonides. *Russ. J. Org. Chem.* 46, 561-567 (2010).
- [15] Shtyrilin, N. V. et al. New synthetic method for 2, 3, 4-tris(hydroxymethyl)-6-methylpyridin-5-ol. *Russ. J. Org. Chem.* 45, 1266-1268 (2009).
- [16] Matschinsky, F. M. & Porte Jr., D. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. *F1000 Med. Rep.* 2 (2010).
- [17] Vassiliev, P. M., Spasov, A. A., Kochetkov, A. N., Vorfolomeeva, V. V. & Yanaliev, L. R. In Target-oriented search for antidiabetic agents 126-181 (VSMU, 2016).
- [18] Trott, O. & Olson, A. J. Software news and update AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* 31, 455-461 (2010).
- [19] Cheruvallath, Z. S. et al. Design, synthesis and SAR of novel glucokinase activators. *Bioorganic Med. Chem. Lett.* 23, 2166-2171 (2013).
- [20] Zelent, B. et al. Mutational analysis of allosteric activation and inhibition of glucokinase. *Biochem. J.* 440, 203-215 (2011).
- [21] Rittié, L. & Fisher, G. J. Isolation and culture of skin fibroblasts. *Methods Mol. Med.* 117, 83-98 (2005).